Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC11A2 | P49281 | 1/20 | 0.40 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 8/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3860956 | 0.86 | GPR35 (0.40) | HMGB1ALOX5METAP2METAP1CXCL8 | |
| SCHEMBL30320123 | 0.77 | PARP1 (0.46) | SLC11A2HMGB1GLASTING1ALOX5 | |
| SCHEMBL198085 | 0.77 | PARP1 (0.46) | SLC11A2HMGB1GLASTING1ALOX5 | |
| Hydrochloric Acid SCHEMBL4433579 | 0.77 | TAAR1 (0.43) | HMGB1CXCL8PTGS2PTGS1 | |
| SCHEMBL11204325 | 0.75 | ALOX5 (0.43) | ALOX5CXCL8PTGS1 | |
| SCHEMBL28843796 | 0.73 | KMT2A (0.41) | SLC11A2HMGB1GLASTING1ALOX5 | |
| SCHEMBL2589150 | 0.70 | SLC11A2 (0.43) | SLC11A2HMGB1ALOX5 | |
| SCHEMBL24819001 | 0.69 | ELANE (0.41) | SLC11A2GLASTING1ALOX5MTNR1A | |
| SCHEMBL13990693 | 0.69 | PARP1 (0.51) | SLC11A2GLASTING1ALOX5PTGER4 | |
| SCHEMBL3026634 | 0.69 | PTGS2 (0.43) | CXCL8PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019011879-A1 | THERAPEUTIC FOR TREATING CAPILLARY LEAK SYNDROME | HENNING RAINER (CH) | 2019-01-17 | — | — | WO | claimed |
| US-8088890-B2 | Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2012-01-03 | — | — | US | claimed |
| EP-2334324-A2 | BBETA (15-42) AND ITS ANALOGUES COMBINED WITH CYCLOSPORINE FOR TREATMENT OF REPERFUSION INJURY | Fibrex Medical Research & Development GmbH (AT) | 2011-06-22 | — | — | EP | claimed |
| EP-2328925-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | Fibrex Medical Research & Development GmbH (AT) | 2011-06-08 | — | — | EP | claimed |
| EP-2274328-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | Fibrex Medical Research & Development GmbH (AT) | 2011-01-19 | — | — | EP | claimed |
| WO-2010043444-A2 | PHARMACEUTICAL PREPARATION FOR THE TREATMENT AND/OR PREVENTION OF ISCHEMIA/REPERFUSION INJURY AND THE SEQUELS THEREOF | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-22 | — | — | WO | claimed |
| WO-2010043972-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-22 | — | — | WO | claimed |
| WO-2010034041-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-01 | — | — | WO | claimed |
| US-20100081787-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-01 | — | — | US | claimed |
| WO-2009137850-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2009-11-19 | — | — | WO | claimed |
| US-20070244041-A1 | Peptide Yy Analogues | REOSCIENCE A/S (DK) | 2007-10-18 | — | — | US | claimed |
| EP-1718671-A2 | PEPTIDE YY ANALOGUES | Rheoscience A/S (DK) | 2006-11-08 | — | — | EP | claimed |
| WO-2005080424-A2 | PEPTIDE YY ANALOGUES | RHEOSCIENCE A/S (DK) | 2005-09-01 | — | — | WO | claimed |
| CN-116348128-A | Bβ15-42 for treating viral endopdermatitis | F4医药有限责任公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-107129538-B | Peptide conjugates of GLP-1 receptor agonists and gastrin and uses thereof | 西兰制药公司 | 2021-07-16 | — | — | CN | disclosed |
| WO-2019011879-A1 | THERAPEUTIC FOR TREATING CAPILLARY LEAK SYNDROME | HENNING RAINER (CH) | 2019-01-17 | — | — | WO | disclosed |
| US-6333402-B1 | FOR THERAPY AND DIAGNOSIS | DYAX CORP. | 2001-12-25 | — | — | US | disclosed |
| US-6057287-A | KUNITZ DOMAIN HAVING DISULFIDE BONDS AT CYSTINE 5-55, 14-38, 30-51 POSITIONS | DYAX CORP. (US) | 2000-05-02 | — | — | US | disclosed |
| US-6034211-A | β-sheet nucleating peptidomimetics | KELLY JEFFERY W (US) | 2000-03-07 | — | — | US | disclosed |
| WO-1997046547-A1 | β-SHEET NUCLEATING PEPTIDOMIMETICS | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081787-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | NGLY1, GHRHR, GHSR | SLC11A2 1558/4885HMGB1 2250/4885GLA 1087/4885 |
| US-20070244041-A1 | Peptide Yy Analogues | NPY1R, NPY2R, NPY4R | SLC11A2 3907/4885HMGB1 2230/4885GLA 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.